Oncology Institute Management
Management criteria checks 1/4
Oncology Institute's CEO is Dan Virnich, appointed in Jun 2023, has a tenure of less than a year. total yearly compensation is $3.24M, comprised of 13.8% salary and 86.2% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth $597.39K. The average tenure of the management team and the board of directors is 1.5 years and 2.5 years respectively.
Key information
Dan Virnich
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 13.8% |
| CEO tenure | less than a year |
| CEO ownership | 0.8% |
| Management average tenure | 1.5yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%
Mar 21
Is Oncology Institute (NASDAQ:TOI) A Risky Investment?
Mar 05The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company
Nov 10The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit
Aug 09Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings
May 18Companies Like Oncology Institute (NASDAQ:TOI) Are In A Position To Invest In Growth
Mar 16The Oncology Institute: Capitalizing On Clinical Research Contracts
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$61m |
| Jun 30 2023 | n/a | n/a | -US$50m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$3m | US$446k | US$68k |
| Sep 30 2022 | n/a | n/a | -US$1m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | US$6m |
| Dec 31 2021 | US$8m | US$263k | -US$11m |
| Sep 30 2021 | n/a | n/a | -US$6m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$419k | US$214k | -US$14m |
Compensation vs Market: Dan's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Virnich (44 yo)
less than a year
Tenure
US$3,244,461
Compensation
Dr. Daniel Virnich, also known as Dan, M.D., MBA, FACHE, is Chief Executive Officer of The Oncology Institute Inc. and served as its President of The Oncology Institute, Inc. since March 15, 2022 until 202...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 4.5yrs | US$447.34k | 0.35% $ 272.6k | |
| Chief Executive Officer | less than a year | US$3.24m | 0.76% $ 597.4k | |
| Chief Financial Officer | 2.1yrs | US$2.36m | 0.15% $ 120.7k | |
| Chief Operations Officer | less than a year | no data | no data | |
| General Counsel | 9.3yrs | no data | no data | |
| Chief Medical Officer | 2.5yrs | US$368.33k | 0.039% $ 30.9k | |
| Chief Development Officer | less than a year | no data | no data |
1.5yrs
Average Tenure
45yo
Average Age
Experienced Management: TOI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 4.5yrs | US$447.34k | 0.35% $ 272.6k | |
| Independent Director | 1.7yrs | US$108.38k | 0.11% $ 86.7k | |
| Vice Chairman | 2.5yrs | US$6.63m | 0.50% $ 393.1k | |
| Independent Director | 2.5yrs | US$251.22k | 0.061% $ 47.8k | |
| Director | 1.7yrs | US$104.34k | 0.039% $ 30.8k | |
| Independent Director | 2.5yrs | US$234.21k | 0.057% $ 45.3k | |
| Independent Director | 4.2yrs | US$239.88k | 0.065% $ 51.1k | |
| Independent Director | 2.5yrs | US$239.88k | 0.059% $ 46.1k |
2.5yrs
Average Tenure
62yo
Average Age
Experienced Board: TOI's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.